Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) issued its earnings results on Thursday. Zentalis Pharmaceuticals Trading Down 15.6%Shares of NASDAQ ZNTL opened at $4.22 on Friday. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies. Featured StoriesReceive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.